The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Genmab; Merck Serono; MSD; Regeneron; Seagen
Speakers' Bureau - AstraZeneca; Eisai; MSD; Roche; Takeda
Research Funding - Abbvie (Inst); Advenchen Laboratories (Inst); Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); BMS (Inst); CanariaBio (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); genemedicine (Inst); Genmab (Inst); GI Innovation (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Janssen Oncology (Inst); Kelun (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); onconic therapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Sutro Biopharma (Inst); Synthon (Inst); Takeda (Inst); Torl Biotherapeutics (Inst); Zymeworks (Inst)
E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).
 
Jung-Yun Lee
No Relationships to Disclose
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Kyowa Kirin; MSD K.K; Regeneron; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; Merck KGaA; MSD K.K; Regeneron; Roche; Sanofi; Takeda; Zymeworks
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Byoung-Gie Kim
No Relationships to Disclose
 
Barry Berman
Employment - Florida Cancer Specialists
Honoraria - Cellectar
Consulting or Advisory Role - Cellectar
 
Shiro Suzuki
Speakers' Bureau - Eisai; MDS KK
 
Bradley Corr
Consulting or Advisory Role - AstraZeneca/Merck (Inst); Corcept Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunogen; Imvax; Merck (Inst); Zentalis (Inst)
Research Funding - Clovis Oncology (Inst); Immunogen (Inst)
 
Mayu Yunokawa
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Eisai; MSD; Sanofi; Takeda
 
Douglas Orr
Employment - Texas Oncology/US Oncology
Research Funding - Mary Crowley Research Center, Dallas Texas
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Mitsubishi Tanabe; Noile-Immune Biotech, Inc; Rakuten Medical Japan
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Pamela Soliman
Consulting or Advisory Role - BIOPHARM; Curio Science; GlaxoSmithKline; Medscape
Research Funding - Leap Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
David Miller
Consulting or Advisory Role - AADi; Aptitude Health; AstraZeneca; Boxer Capital; Cardinal Health; Clinical Education Alliance; Clinical Education Alliance; Curio Science; Eisai; Eisai Europe; GlaxoSmithKline; IDEOlogy Health; Intellisphere; InVitae; Karyopharm Therapeutics; Merck Sharp & Dohme; Mural Oncology; Prime Education
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Akeso Biopharma (Inst); Aprea AB (Inst); AstraZeneca (Inst); EMD Serono; Immunogen (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics; Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); NVision (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Takatoshi Sahara
Employment - Eisai
 
Lea Dutta
Employment - Eisai
 
Jincao Wu
Employment - Eisai
 
Jodi McKenzie
Employment - Eisai
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; ESMO Congress; Merck
Other Relationship - IBM